Trevena — Patent Portfolio
1 drug with active patents · 15 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Trevena's pharmaceutical portfolio is moderately strong, with a significant cliff year in 2032 and no revenue at risk in the next 5 years.
Portfolio overview Trevena has a total of 1 drug with patents, out of 1 total drugs in their portfolio. The company has 15 active US patents, with an average vulnerability score of 71. Notably, there are no ironclad patents, but 3 vulnerable patents. Additionally, there are no biologics in the portfolio.
Cliff calendar In 2032, 1 drug will lose exclusivity, including Olinvyk. This marks a significant cliff year for the company.
Most exposed drugs The top drug facing near-term loss of exclusivity is Olinvyk, with an earliest active patent expiry date of 2032-03-23, an average vulnerability score of 71, and no annual revenue data available. This drug has 15 patents.
Biologic exclusivity There are no biologics in the portfolio, meaning there is no BPCIA 12-year reference product exclusivity to consider.
Strategic implications With no revenue at risk in the next 5 years, Trevena has an opportunity to focus on lifecycle management strategies, such as subQ switches, label extensions, or combination filings, to maintain revenue growth.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Olinvyk (OLICERIDINE)
Cliff 2032 · 6y-
US11931350
Vuln 81
2032-03-23
This patent protects methods of using opioid receptor ligands, such as Olinvyk, for treating pain and pain-related disorders.
-
US11931350
Vuln 81
2032-03-23
This patent protects methods of using opioid receptor ligands, such as Olinvyk, for treating pain and pain-related disorders.
-
US11931350
Vuln 81
2032-03-23
This patent protects methods of using opioid receptor ligands, such as Olinvyk, for treating pain and pain-related disorders.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 15 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Trevena's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export